Latest news

• Merck finally bags FDA approval for Bridion

  The US FDA has approved Merck &Co's Bridion to reverse the effects of neuromuscular blockade induced by muscle relaxants used during surgery. ... Merck said it plans to launch Bridion in January and will announce Bridion's price at that time.

• At long last, Merck gets FDA panel backing for Bridion

  After several knockbacks, Merck &Co has finally moved a key step closer to securing FDA approval for its muscle relaxant reversal agent Bridion. ... Bridion (sugammadex) was first rejected by the FDA in 2008, and was turned down once again in 2013.

• Merck faces another Bridion knockback

  Merck maintains that Bridion provides faster and more complete reversal of neuromuscular blockade than the older drugs and has a lesser effect on heart rate. ... Bridion was acquired by Merck when it took over Schering-Plough in 2009.

• R&D in the firing line as Merck & Co axes 8,500 jobs

  Recent setbacks in Merck's late-stage pipeline include a delay in US approval of anaesthesia drug Bridion (sugammadex) and an FDA rejection for insomnia candidate suvorexant, while the company has

• FDA rejects Merck muscle relaxant drug once again

  Regulator still has hypersensitivity concerns about Bridion. Merck &Co's muscle relaxant Bridion has been available in the EU for five years, but the company has once again failed to convince ... reactions that was requested by the FDA when it turned